Dual targeting OX40 and IL-2 receptor enhances antitumor activity through tumor-infiltrating Treg depletion and CD8+ T-cell proliferation

作者
Shuaishuai Cao,Zhichen Sun,Wenbo Hu,Diyuan Xue,Zuming Yang,Pengfei Duan,Hua Peng,Yang–Xin Fu,Yong Liang
出处
期刊:Journal for ImmunoTherapy of Cancer [BMJ]
卷期号:13 (9): e011638-e011638
标识
DOI:10.1136/jitc-2025-011638
摘要

Background The strong regulatory T cell (Treg) inhibitory activity and dysfunctional cytotoxic T lymphocytes (CTLs) represent major barriers to effective antitumor immunity, particularly in late-stage cancer. Multiple anti-OX40 (aOX40) agonistic antibodies have been developed but exhibit limited antitumor efficacy. Interleukin-2 (IL-2) effectivity expands CTLs but has severe side effects. Methods We construct an aOX40-mIL2-Fc bispecific antibody through Fab physical blocking and attenuated IL-2 with Rβ reducing N88D mutation. We also produced aOX40-Fc and IL-2/aOX40-Fc as a comparison using the 293F expression system. Single-cell and flow cytometry were used to analyze the change of T-cell subsets in the tumor microenvironment (TME). Mouse tumor models were used to assess the antitumor efficacy of aOX40-mIL2-Fc by tumor growth and survival, and toxicity by body weight loss, inflammatory cytokine production, and natural killer (NK) cell proliferation in the blood. The tumor-bearing mice were randomly assigned, and the average size was similar among various groups. Results aOX40-mIL2-Fc bispecific antibody-cytokine exhibited a synergistic therapeutic effect with limited toxicity, outperforming IL-2-Fc or aOX40 alone treatment, and conferring resistance to tumor rechallenge. On cellular mechanisms, aOX40-mIL2-Fc treatment showed great Treg depletion and increased both stem-like and effector functional terminal CD8 + T cells in the TME, while avoiding NK cells expansion in the periphery. Furthermore, this bispecific antibody remarkably improved the anti-programmed death-ligand 1 (PD-L1) therapeutic effect. Conclusions Our study unveils a novel approach to IL-2 design that addresses several critical shortcomings of existing strategies and elucidates the cellular mechanisms underlying aOX40-mIL2-Fc therapy. Meanwhile, combining aOX40-mIL2-Fc with PD-L1 blockade represents a strategic approach to enhance tumor control and overcome resistance to immune checkpoint blockade therapies synergistically.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lulibohan完成签到,获得积分10
刚刚
高大摇伽的应助被听书予你采纳,获得10
刚刚
刚刚
小叮当发布了新的文献求助30
1秒前
shidewu发布了新的文献求助10
1秒前
1秒前
心奈11完成签到,获得积分10
1秒前
2秒前
Yang完成签到 ,获得积分10
2秒前
3秒前
CodeCraft的应助被Laila采纳,获得10
4秒前
linyyy完成签到,获得积分10
4秒前
lqq完成签到,获得积分10
5秒前
5秒前
GingerF的应助被chrisio采纳,获得50
5秒前
DW的应助被LFQlfc采纳,获得10
5秒前
6秒前
6秒前
大模型的应助被yian007采纳,获得10
6秒前
ke发布了新的文献求助10
7秒前
刘放发布了新的文献求助10
7秒前
安详的梦秋完成签到,获得积分20
8秒前
有点礼貌但不多完成签到 ,获得积分20
8秒前
8秒前
xing_xing的应助被QQ糖采纳,获得20
9秒前
9秒前
10秒前
456发布了新的文献求助10
11秒前
11秒前
Hello的应助被杰斯顿采纳,获得10
12秒前
13秒前
Dr.XX完成签到,获得积分10
13秒前
13秒前
欣喜成仁完成签到,获得积分10
13秒前
ywl发布了新的文献求助10
13秒前
今后的应助被无限的尔安采纳,获得10
14秒前
Kyone完成签到,获得积分10
14秒前
chen完成签到,获得积分10
14秒前
看到就去签到完成签到,获得积分10
15秒前
molihuakai的应助被盒子采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178341
求助须知:如何正确求助?哪些是违规求助? 9569073
关于积分的说明 21802629
捐赠科研通 7773188
什么是DOI,文献DOI怎么找? 3432780
关于科研通互助平台的介绍 2556770
邀请新用户注册赠送积分活动 2478298